HK1151226A1 - Therapeutic agent for pruritus - Google Patents
Therapeutic agent for pruritusInfo
- Publication number
- HK1151226A1 HK1151226A1 HK11105302.9A HK11105302A HK1151226A1 HK 1151226 A1 HK1151226 A1 HK 1151226A1 HK 11105302 A HK11105302 A HK 11105302A HK 1151226 A1 HK1151226 A1 HK 1151226A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pruritus
- therapeutic agent
- therapeutic
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007315144 | 2007-12-05 | ||
PCT/JP2008/072142 WO2009072598A1 (fr) | 2007-12-05 | 2008-12-05 | Agent thérapeutique contre le prurit |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1151226A1 true HK1151226A1 (en) | 2012-01-27 |
Family
ID=40717776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11105302.9A HK1151226A1 (en) | 2007-12-05 | 2011-05-27 | Therapeutic agent for pruritus |
HK15101091.9A HK1200697A1 (en) | 2007-12-05 | 2015-02-02 | Therapeutic agent for pruritus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101091.9A HK1200697A1 (en) | 2007-12-05 | 2015-02-02 | Therapeutic agent for pruritus |
Country Status (14)
Country | Link |
---|---|
US (1) | US8431127B2 (fr) |
EP (1) | EP2241332A4 (fr) |
JP (1) | JP5475460B2 (fr) |
KR (1) | KR101595134B1 (fr) |
CN (2) | CN101939025B (fr) |
AU (1) | AU2008332276B2 (fr) |
BR (1) | BRPI0821145B8 (fr) |
CA (1) | CA2708065C (fr) |
HK (2) | HK1151226A1 (fr) |
MX (1) | MX2010006097A (fr) |
MY (2) | MY185647A (fr) |
RU (2) | RU2596397C2 (fr) |
TW (1) | TWI441649B (fr) |
WO (1) | WO2009072598A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CL2007001665A1 (es) | 2006-06-08 | 2008-01-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria. |
CA2700394C (fr) | 2007-09-26 | 2017-10-24 | Chugai Seiyaku Kabushiki Kaisha | Region constante d'anticorps modifie |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
AU2008332271C1 (en) | 2007-12-05 | 2014-04-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-NR10 antibody and use thereof |
US8431127B2 (en) | 2007-12-05 | 2013-04-30 | Chugai Seiyaku Kabushiki Kaisha | Method for treating pruritus comprising administering an NR10 antagonist |
CN107551270A (zh) | 2008-04-11 | 2018-01-09 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
WO2010107110A1 (fr) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | Variant d'une région constante d'anticorps |
CA2797856C (fr) | 2010-04-30 | 2018-09-18 | Alexion Pharmaceuticals, Inc. | Anticorps anti-c5a et methodes pour utiliser les anticorps |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
US9770195B2 (en) * | 2012-08-09 | 2017-09-26 | The Regents Of The University Of California | Automated scratch detection system and signal processing algorithm for the study of pruritus in animals |
KR102514173B1 (ko) | 2015-04-14 | 2023-03-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
CA2980992C (fr) * | 2015-04-14 | 2024-01-23 | Akihisa Kaneko | Composition pharmaceutique pour la prevention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
EP3322725A1 (fr) | 2015-07-16 | 2018-05-23 | Eli Lilly and Company | Traitement du prurit |
CN110563844A (zh) * | 2019-09-04 | 2019-12-13 | 华中农业大学 | 一种抗犬白介素31受体的多克隆抗体及其应用 |
TW202128222A (zh) | 2019-11-20 | 2021-08-01 | 日商中外製藥股份有限公司 | 含有抗體之製劑 |
MX2023002482A (es) | 2020-09-01 | 2023-03-08 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. |
WO2022178201A1 (fr) * | 2021-02-22 | 2022-08-25 | Zoetis Services Llc | Modèle de prurit induit par l'il-31 équine |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JP2898064B2 (ja) | 1989-08-03 | 1999-05-31 | 忠三 岸本 | ヒトgp130蛋白質 |
EP0585287B1 (fr) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
GB9016440D0 (en) | 1990-07-26 | 1990-09-12 | Elopak Systems | A laminate |
WO1993012227A1 (fr) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Animaux transgeniques non humains capables de produire des anticorps heterologues |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
CA2119930C (fr) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production d'anticorps chimeres - demarche combinatoire |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
WO1993019172A1 (fr) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Procedes de production d'elements de paires de liaison specifiques |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
BR9204244A (pt) | 1992-10-26 | 1994-05-03 | Cofap | Ferro fundido cinzento |
WO1994012215A1 (fr) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Anticorps humanises reagissant avec l-selectine |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (fr) | 1993-12-03 | 1995-06-08 | Medical Research Council | Proteines et peptides de liaison recombines |
US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
CA2194907A1 (fr) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
FR2729855A1 (fr) * | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
AUPN481295A0 (en) | 1995-08-16 | 1995-09-07 | Medvet Science Pty. Ltd. | Agonists of haemopoietic growth factors |
JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン5受容体α鎖に対する抗体 |
AUPN564195A0 (en) | 1995-09-26 | 1995-10-19 | Walter And Eliza Hall Institute Of Medical Research, The | A novel haemopoietin receptor and genetic sequences encoding same |
DE69638050D1 (de) | 1995-10-23 | 2009-11-19 | Zenyth Operations Pty Ltd | Hemopoietin-rezeptor und dafür kodierende genetische sequenzen |
US6642360B2 (en) | 1997-12-03 | 2003-11-04 | Genentech, Inc. | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
AU759689B2 (en) | 1998-06-24 | 2003-04-17 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor proteins |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
CA2374391C (fr) | 1999-06-01 | 2014-10-28 | Schering Corporation | Proteines de recepteur mammaliennes, reactifs et procedes y relatifs |
US20030082734A1 (en) | 1999-06-01 | 2003-05-01 | Dowling Lynette M. | Mammalian receptor proteins; related reagents and methods |
EP1188830B1 (fr) | 1999-06-02 | 2010-01-20 | Chugai Seiyaku Kabushiki Kaisha | Proteine receptrice d'hemopoietine |
WO2001023556A1 (fr) | 1999-09-27 | 2001-04-05 | Chugai Seiyaku Kabushiki Kaisha | Nouvelle proteine receptrice d'hemopoietine (nr12) |
EP1918377B1 (fr) | 2000-05-10 | 2013-12-04 | Merck Sharp & Dohme Corp. | Protéines de récepteur de mammifère; réactifs et procédés associés |
US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
DK1325115T3 (en) | 2000-06-26 | 2016-11-21 | Zymogenetics Inc | CYTOKINRECEPTOR ZCYTOR17 |
US20030059871A1 (en) | 2000-10-06 | 2003-03-27 | Cosman David J. | Hematopoietin receptors HPR1 and HPR2 |
WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
AU2003225525B2 (en) | 2002-01-18 | 2008-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
ATE547430T1 (de) | 2002-01-18 | 2012-03-15 | Zymogenetics Inc | Multimere des cytokinrezeptors zcytor17 |
EP2110434A1 (fr) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Recepteur de cytokine de type 1 GLM-R |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
ES2354419T3 (es) | 2002-05-01 | 2011-03-14 | Bayer Schering Pharma Aktiengesellschaft | Nuevas proteínas de fusión de trombomodulina dirigidas hacia el factor tisular como agentes anticoagulantes. |
WO2003104453A1 (fr) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | Procede de construction d'anticorps |
US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
WO2004091543A2 (fr) | 2003-03-04 | 2004-10-28 | Alexion Pharmaceuticals, Inc. | Procede de traitement de maladies auto-immunes en suscitant une presentation d'antigenes par des cellules presentant des antigenes inductrices de tolerance |
US20060134756A1 (en) | 2003-03-24 | 2006-06-22 | Wenfeng Xu | Anti-IL-20 antibodies and binding partners and methods of using in inflammation |
TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
AU2005259992A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
EP1671642A1 (fr) | 2004-12-15 | 2006-06-21 | Universite D'angers | Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes |
HUE026107T2 (en) | 2004-12-28 | 2016-05-30 | Innate Pharma | Monoclonal antibody to NKG2A |
JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス,インコーポレイティド | Il−31の均質調製物 |
MX2007009577A (es) | 2005-02-14 | 2008-01-30 | Zymogenetics Inc | Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31. |
EP1858924A1 (fr) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methodes de traitement d'affections de la peau en employant un antagoniste de il-31ra |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7531637B2 (en) | 2005-05-06 | 2009-05-12 | Zymogenetics, Inc. | IL-31 monoclonal antibodies |
EP2001906A2 (fr) | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | PROCÉDÉS DE TRAITEMENT DE LA DOULEUR ET DE L'INFLAMMATION DANS LE TISSU NEURONAL METTANT EN OEUVRE DES ANTAGONISTES IL-31Ra ET OSMRb |
CL2007001665A1 (es) | 2006-06-08 | 2008-01-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria. |
WO2007147122A2 (fr) | 2006-06-15 | 2007-12-21 | The Board Of Trustees Of The University Of Arkansas | Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine |
WO2008100995A1 (fr) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Anticorps humains anti-cd100 |
AU2008218968B2 (en) | 2007-02-23 | 2013-10-17 | Merck Sharp & Dohme Llc | Engineered anti-IL-23p19 antibodies |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
WO2009041621A1 (fr) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps du récepteur anti-il-6 |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
CA2700394C (fr) | 2007-09-26 | 2017-10-24 | Chugai Seiyaku Kabushiki Kaisha | Region constante d'anticorps modifie |
AU2008332271C1 (en) | 2007-12-05 | 2014-04-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-NR10 antibody and use thereof |
US8431127B2 (en) | 2007-12-05 | 2013-04-30 | Chugai Seiyaku Kabushiki Kaisha | Method for treating pruritus comprising administering an NR10 antagonist |
-
2008
- 2008-12-05 US US12/746,229 patent/US8431127B2/en active Active
- 2008-12-05 BR BRPI0821145A patent/BRPI0821145B8/pt active IP Right Grant
- 2008-12-05 MX MX2010006097A patent/MX2010006097A/es active IP Right Grant
- 2008-12-05 JP JP2009544731A patent/JP5475460B2/ja active Active
- 2008-12-05 RU RU2014150548/10A patent/RU2596397C2/ru active
- 2008-12-05 AU AU2008332276A patent/AU2008332276B2/en active Active
- 2008-12-05 MY MYPI2016002081A patent/MY185647A/en unknown
- 2008-12-05 KR KR1020107014699A patent/KR101595134B1/ko active IP Right Grant
- 2008-12-05 TW TW097147375A patent/TWI441649B/zh active
- 2008-12-05 CN CN200880126534.1A patent/CN101939025B/zh active Active
- 2008-12-05 RU RU2010127291/10A patent/RU2541780C2/ru active
- 2008-12-05 EP EP08857461A patent/EP2241332A4/fr not_active Withdrawn
- 2008-12-05 CN CN201410451948.9A patent/CN104162155A/zh active Pending
- 2008-12-05 CA CA2708065A patent/CA2708065C/fr active Active
- 2008-12-05 MY MYPI2010002563A patent/MY162546A/en unknown
- 2008-12-05 WO PCT/JP2008/072142 patent/WO2009072598A1/fr active Application Filing
-
2011
- 2011-05-27 HK HK11105302.9A patent/HK1151226A1/xx unknown
-
2015
- 2015-02-02 HK HK15101091.9A patent/HK1200697A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101939025A (zh) | 2011-01-05 |
EP2241332A4 (fr) | 2011-01-26 |
TW200932265A (en) | 2009-08-01 |
JP5475460B2 (ja) | 2014-04-16 |
KR101595134B1 (ko) | 2016-02-17 |
CN101939025B (zh) | 2015-03-25 |
RU2014150548A (ru) | 2015-07-20 |
HK1200697A1 (en) | 2015-08-14 |
RU2010127291A (ru) | 2012-01-10 |
MY162546A (en) | 2017-06-15 |
MX2010006097A (es) | 2010-08-04 |
BRPI0821145B1 (pt) | 2019-10-15 |
AU2008332276B2 (en) | 2014-02-27 |
KR20100100935A (ko) | 2010-09-15 |
WO2009072598A1 (fr) | 2009-06-11 |
MY185647A (en) | 2021-05-27 |
RU2596397C2 (ru) | 2016-09-10 |
BRPI0821145A2 (pt) | 2015-06-16 |
TWI441649B (zh) | 2014-06-21 |
AU2008332276A1 (en) | 2009-06-11 |
BRPI0821145B8 (pt) | 2021-05-25 |
EP2241332A1 (fr) | 2010-10-20 |
CA2708065A1 (fr) | 2009-06-11 |
JPWO2009072598A1 (ja) | 2011-04-28 |
CN104162155A (zh) | 2014-11-26 |
US8431127B2 (en) | 2013-04-30 |
CA2708065C (fr) | 2015-02-24 |
US20100310556A1 (en) | 2010-12-09 |
RU2541780C2 (ru) | 2015-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200697A1 (en) | Therapeutic agent for pruritus | |
EP2117311A4 (fr) | Agents thérapeutiques | |
EP2211620A4 (fr) | Composés thérapeutiques | |
EP2127671A4 (fr) | Agent therapeutique contre le cancer | |
HRP20130041T8 (en) | Therapeutic agents | |
EP2123253A4 (fr) | Agent de prévention et de modification des rides | |
GB0716532D0 (en) | Therapeutic compounds | |
GB0813087D0 (en) | Therapeutic compounds | |
EP2236594A4 (fr) | Agent d'élimination d'un biolfilm | |
GB0723747D0 (en) | Therapeutic agents | |
ZA201100904B (en) | Therapeutic agent for migraine | |
EP2164324A4 (fr) | Composés thérapeutiques | |
EP2221057A4 (fr) | Agent améliorant les sens | |
EP2185568A4 (fr) | Composés thérapeutiques | |
EP2168955A4 (fr) | Agent d'amélioration du sommeil | |
EP2140876A4 (fr) | Agent thérapeutique comprenant de la vasohibine | |
EP2172195A4 (fr) | Agent à effet hypocholestérolémiant | |
GB0702862D0 (en) | Therapeutic compounds | |
GB0701321D0 (en) | Agent | |
GB0723748D0 (en) | Therapeutic agents | |
ZA201003835B (en) | Therapeutic agent for ulcer | |
EP2324827A4 (fr) | Agent thérapeutique pour une angéite liée à anca | |
GB0708188D0 (en) | Therapeutic compounds | |
EP2206510A4 (fr) | Agent thérapeutique pour le diabète | |
GB0723751D0 (en) | Therapeutic agents |